Cost effectiveness and resource allocation : C/E
Cost-effectiveness of lenvatinib plus pembrolizumab as the second-line treatment for advanced endometrial carcinoma.
Szu-Ting Chiang, Chen-Han Chueh, Yu-Wen Wen, Shao-Chin Chiang, Wai-Hou Li, Yi-Wen Tsai
Published: 202610.1186/s12962-025-00711-y
No abstract available for this study.